Efficacy and safety of febuxostat in Japanese paediatric patients with hyperuricaemia including gout: Phase 2, single arm, open‒label, multicentre studies
In paediatric patients with hyperuricaemia including gout, febuxostat showed long-term, well-controlled urate-lowering efficacy with no major safety issues. Findings suggest that no dose adjustment is required for paediatric patients with mild to moderate renal dysfunction.
Authors
- Akihiro Nakajima (ORCID: https://orcid.org/0000-0003-4992-2586)
- Hisashi Yamanaka (ORCID: https://orcid.org/0000-0001-8453-6731)
- Shuichi Ito (ORCID: https://orcid.org/0000-0002-5242-8987)
- Masataka Honda (ORCID: https://orcid.org/0000-0002-4696-314X)
- Makoto Nitami
- Yo Morita
- Ryutaro Iwama (ORCID: https://orcid.org/0009-0003-1341-7470)
Institutions
- Institute of Rheumatology (CZ)
- Tokyo Women's Medical University (JP)
- Tokyo Metropolitan Children's Medical Center (JP)
- Sanno Medical Center (JP)
- International University of Health and Welfare (JP)
- Yokohama City University (JP)
- Teijin (Japan) (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1093/mr/roae056
- Citations
- 2
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.68
Funders
- National Center for Child Health and Development
- Tokyo Women's Medical University
- Teijin Pharma